martes, 29 de julio de 2014

Isolated Cancer Cells May Lead to Personalized Treatments - NIH Research Matters - National Institutes of Health (NIH)

Isolated Cancer Cells May Lead to Personalized Treatments - NIH Research Matters - National Institutes of Health (NIH)

National Institutes of Health (NIH) - Turning Discovery Into Health

Contact Us

Mailing Address:
NIH Research Matters
Bldg. 31, Rm. 5B64A, MSC 2094
Bethesda, MD 20892-2094

About NIH Research Matters

Editor: Harrison Wein, Ph.D.
Assistant Editors: Vicki Contie, Carol Torgan, Ph.D.
NIH Research Matters is a weekly update of NIH research highlights from the Office of Communications and Public Liaison, Office of the Director, National Institutes of Health.

Isolated Cancer Cells May Lead to Personalized Treatments

At a Glance

  • Scientists used a novel microchip-based method to isolate and grow tumor cells circulating in blood.
  • The technique provides an opportunity to test treatments on tumor cells, an important step toward personalizing cancer therapy.
Cells shed from tumors enter the bloodstream in very low numbers and circulate through the body. These circulating tumor cells (CTCs) can take root elsewhere, causing the spread of the cancer to other organs, a process called metastasis. As cancers grow and spread, they can undergo genetic mutations that enable them to become resistant to treatment and survive and grow at metastatic sites. The isolation and analysis of CTCs may thus be a useful method for tracking how cancers evolve during therapy.
Circulating tumor cells from the blood of a breast cancer patient. Image by Maria C. Donaldson and Min Yu.
Isolating these rare CTCs from the blood of cancer patients, however, has been a technical challenge. Recently, researchers developed a way to isolate CTCs using microfluidic technology. The microchip device, called the CTC-iChip, enriches CTCs by removing blood cells. As the method doesn’t rely on any cell-surface proteins expressed by tumor cells, it can be applied to virtually all cancers.
In their new study, the research team—led by Drs. Shyamala Maheswaran and Daniel A. Haber of Massachusetts General Hospital and Harvard Medical School—used the CTC-iChip to establish cell cultures from breast cancer patients. The work was funded in part by NIH’s National Cancer Institute (NCI) and National Institute of Biomedical Imaging and Bioengineering (NIBIB). The study was published on July 11, 2014, in Science.
The scientists collected blood samples from 36 patients with metastatic, estrogen-receptor-positive breast cancers. Using the CTC-iChip, the researchers isolated CTCs from these samples and were able to establish cell lines from 6 of the patients. They found that 3 of 5 tested cell lines formed tumors when injected into mice.
The CTC lines proved to be genetically different than the original tumors. Newly acquired mutations were found in several cancer-associated genes: fibroblast growth factor receptor (FGFR2), PIK3CATP53KRAS, and estrogen receptor (ESR1).
The researchers tested a number of drugs on the cells to find better therapies to treat the cancers. They found that different combinations of drugs were effective against tumors carrying these acquired mutations.
“This approach of culturing circulating cancer cells in the blood, analyzing them for new mutations that have developed during therapy, and testing the utility of drugs targeting those mutations could become the essence of individually adjusted cancer therapy in the future,” Haber says.

One major challenge before this strategy could be used in the clinic will be to make it easier to establish CTC lines from patients. “We need to improve culture techniques before this is ready for clinical use, and we are working on doing that right now,” Maheswaran says.
—by Shu Hui Chen, Ph.D.


Reference: Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Yu M, Bardia A, Aceto N, Bersani F, Madden MW, Donaldson MC, Desai R, Zhu H, Comaills V, Zheng Z, Wittner BS, Stojanov P, Brachtel E, Sgroi D, Kapur R, Shioda T, Ting DT, Ramaswamy S, Getz G, Iafrate AJ, Benes C, Toner M, Maheswaran S, Haber DA. Science. 2014 Jul 11;345(6193):216-20. doi: 10.1126/science.1253533. PMID: 25013076.
Funding: NIH’s National Cancer Institute (NCI) and National Institute of Biomedical Imaging and Bioengineering (NIBIB); Breast Cancer Research Foundation, Stand Up to Cancer, the Wellcome Trust, National Foundation for Cancer Research, Susan G. Komen for the Cure, and the Howard Hughes Medical Institute.

No hay comentarios:

Publicar un comentario